GLUE — Monte Rosa Therapeutics, Inc.
GLUE dilution and offerings
- Dilution risk: Low
- Active shelf: S-3ASR (Feb 2026)
- Float: 49.3M shares
🔔 Alert me if GLUE files an offering or S-3
$10.63-1.21%
Last close: · regular session
Last 60 sessions
Dilution risk: low; active automatic shelf (S-3ASR, Feb 2026). Float: 49.3M shares. Latest SEC filing: 8-K on Sep 8, 2026. GLUE closed at $10.63 (-1.21%) on Nov 2, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for GLUE in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Select
- Employees: 142
- Website: https://www.monterosatx.com
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Latest SEC filings for GLUE
Latest GLUE news
- Wall Street Analysts See a 152.87% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High? Read article
- Are Options Traders Betting on a Big Move in Monte Rosa Therapeutics Stock? Read article
- Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.